NEW YORK (GenomeWeb News) – Molecular diagnostics firm QuanDx announced on Thursday the closing of its Series B financing round raising $1.25 million.

Proceeds will go toward further development of its platform technology and its commercial program in oncology, genetic diseases, and infectious diseases. The Menlo Park, Calif.-based company did not disclose the names of the investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.